Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.77 |
| ▸ | CTSB | P07858 | 13/20 | 0.65 |
| ▸ | CTSK | P43235 | 6/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.61 |
| ▸ | ELANE | P08246 | 2/20 | 0.61 |
| ▸ | CTSV | O60911 | 1/20 | 0.61 |
| ▸ | PLG | P00747 | 1/20 | 0.61 |
| ▸ | CMA1 | P23946 | 1/20 | 0.61 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13245534 | 1.00 | CTSL (0.77) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL13267073 | 1.00 | CTSL (0.77) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL13245467 | 1.00 | CTSL (0.77) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL8279522 | 0.90 | CTSL (0.62) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL13016703 | 0.90 | CTSL (0.62) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL13413338 | 0.90 | CTSL (0.62) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL8279523 | 0.90 | CTSL (0.62) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL13062724 | 0.90 | CTSL (0.62) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL13413341 | 0.90 | CTSL (0.62) | CTSLCTSBCTSKABCG2CTSS | |
| SCHEMBL13267111 | 0.89 | CTSB (0.75) | CTSLCTSBCTSKABCG2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468744-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | CTSL 16/4885CTSB 39/4885CTSK 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.